Khavir A. Sharieff, DO

Khavir A. Sharieff, DO
Inova Transplant Center at Inova Fairfax Hospital, Falls Church, VA

David Duncan, MD
Department of Medicine at Inova Fairfax Hospital, Falls Church, VA

Zobair Younossi, MD, MPH
Center for Liver Diseases, Inova Transplant Center and Department of Medicine at Inova Fairfax Hospital, Falls Church, VA

Address: Zobair M. Younossi, MD, MPH, Center for Liver Diseases, Inova Fairfax Hospital, 3300 Gallows Rd., Falls Church, VA 22042; e-mail: zobiar.younossi@inova.com

Dr. Younossi has indicated that he has received grant or research support from the Roche and Schering-Plough corporations and is on the speakers’ bureaus of the Axcan Pharma, Roche, and Schering-Plough corporations.

This paper discusses therapies that are not approved by the US Food and Drug Administration (FDA) for the use under discussion.

Khavir A. Sharieff, DO
Inova Transplant Center at Inova Fairfax Hospital, Falls Church, VA

David Duncan, MD
Department of Medicine at Inova Fairfax Hospital, Falls Church, VA

Zobair Younossi, MD, MPH
Center for Liver Diseases, Inova Transplant Center and Department of Medicine at Inova Fairfax Hospital, Falls Church, VA

Address: Zobair M. Younossi, MD, MPH, Center for Liver Diseases, Inova Fairfax Hospital, 3300 Gallows Rd., Falls Church, VA 22042; e-mail: zobiar.younossi@inova.com

Dr. Younossi has indicated that he has received grant or research support from the Roche and Schering-Plough corporations and is on the speakers’ bureaus of the Axcan Pharma, Roche, and Schering-Plough corporations.

This paper discusses therapies that are not approved by the US Food and Drug Administration (FDA) for the use under discussion.

Khavir A. Sharieff, DO
Inova Transplant Center at Inova Fairfax Hospital, Falls Church, VA

David Duncan, MD
Department of Medicine at Inova Fairfax Hospital, Falls Church, VA

Zobair Younossi, MD, MPH
Center for Liver Diseases, Inova Transplant Center and Department of Medicine at Inova Fairfax Hospital, Falls Church, VA

Address: Zobair M. Younossi, MD, MPH, Center for Liver Diseases, Inova Fairfax Hospital, 3300 Gallows Rd., Falls Church, VA 22042; e-mail: zobiar.younossi@inova.com

Dr. Younossi has indicated that he has received grant or research support from the Roche and Schering-Plough corporations and is on the speakers’ bureaus of the Axcan Pharma, Roche, and Schering-Plough corporations.

This paper discusses therapies that are not approved by the US Food and Drug Administration (FDA) for the use under discussion.